Breaking News, Collaborations & Alliances

Cylene, TetraGene in Anticancer Alliance

Aims to advance Quarfloxin and associated anticancer technologies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cylene Pharmaceuticals and TetraGene have entered into an exclusive, worldwide option and license Agreement allowing TetraGene to advance the development of Quarfloxin and Cylene’s associated anticancer quadruplex-targeting technologies. Cylene will receive an undisclosed upfront fee, as well as potential milestone payments and royalties on product sales. TetraGene has the option to acquire worldwide rights to the technologies licensed from Cylene, which include the Phase II compound Quarf...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters